lsd was once believed to be a useful treatment for what illness?

Neuropsychopharmacology. 2017 Oct; 42(11): 2105–2113.

Published online 2017 May 17. Prepublished online 2017 Apr 26. doi:10.1038/npp.2017.84

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Time to come

Robin L Carhart-Harris

^onePsychedelic Research Group, Middle for Psychiatry, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK

Guy K Goodwin

^twoUniversity of Oxford Department of Psychiatry and Oxford Wellness NHS Foundation Trust, Warneford Hospital, Oxford, Uk

Received 2017 Mar 21; Revised 2017 Apr ten; Accepted 2017 Apr 20.

Abstract

Constitute-based psychedelics, such equally psilocybin, have an aboriginal history of medicinal use. Afterwards the showtime English report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used about notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such every bit LSD showed initial therapeutic hope earlier prohibitive legislature in the mid-1960s finer ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic enquiry: last year saw reports on the outset modern brain imaging report with LSD and three split up clinical trials of psilocybin for depressive symptoms. In this circumspective slice, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic enquiry, with a focus on the development of psilocybin as a treatment for depression.

The therapeutic potential of psychedelic drugs: tempered optimism (RLC-H)

"Your assumptions are your windows on the world. Scrub them off every once in a while, or the calorie-free won't come in." (Isaac Asimov, 1919–1992)

A BRIEF HISTORY OF PSYCHEDELIC RESEARCH

Psychedelic drugs (Psychedelic is a neologism that combines the words psychē (ψ υ χ ?, 'soul') and dēloun (δ η λ ? ? ν, 'to make visible, to reveal'), to announce 'listen-revealing' in reference to the category of drugs in question. I use the term in preference to 'hallucinogens' due to the latter'south arguably misleading accent on these compounds' hallucinogenic properties. When using the term 'psychedelics' I refer to those compounds with appreciable serotonin 2A receptor agonist properties that can change consciousness in a marked and novel fashion. LSD can exist considered the prototypical or 'reference-standard' psychedelic.) awakened a significant cultural zeitgeist in mid-twentieth century (Stevens, 1987, see Table ane). Catalyzed by early reports on the unique authorisation and remarkable subjective furnishings of lysergic acid diethylamide (LSD) in the early 1950s, psychedelics, and particularly LSD, became widely used by psychologists and psychiatrists in research and clinical practice, with tens of thousands of patients estimated to have been treated with 'psychedelic psychotherapy' over a catamenia of nigh 15 years (Grinspoon and Bakalar, 1979). From the mid-60s, psychedelic research was increasingly prevented from having the chapters to inform and potentially advance thinking and practice in psychology and psychiatry, simply as pop and countercultural movements increasingly embraced the drugs, their societal affect skyrocketed (Grinspoon and Bakalar, 1979; Lee and Shlain, 1992; Stevens, 1987).

Table 1

Notable Landmarks of Mid-Twentieth Century Psychedelic Enquiry Plus Events of Cultural Significance

Twelvemonth	Landmark	References
1943	LSD's psychoactive effects discovered by Albert Hofmann (16th and 19th April)	Hofmann, 1980
1947	Werner Stoll publishes first paper on psychological effects of LSD in humans	Stoll, 1947
1950	First English language publication on LSD	Busch and Johnson, 1950
c. 1953	ACNP Founding president Joel Elkes (President in 1961) publishes on LSD after openly self-experimenting with information technology	Bradley et al, 1953; Roberts, 2008
1954	Aldous Huxley's 'The Doors of Perception' published: documents mescaline cocky-experiment	Huxley, 1954
1956	Term 'psychedelic' coined past Humphrey Osmond in communication with Aldous Huxley	Huxley, 1980
1957	Term 'magic mushrooms' coined by LIFE magazine	Wasson, 1957
1958	Identification of psilocybin in magic mushrooms by Albert Hofmann	Hofmann et al, 1958
1959	Closed briefing held in Princeton on 'the use of LSD in psychotherapy', Jonathan Cole attends, an early ACNP president	Abramson, 1959
1960	Commencement major European conference on psychedelics; Sidney Cohen publishes positive meta-analysis on LSD prophylactic	Passie, 1996; Cohen, 1960
1961	Jonathan Cole (ACNP president 1965-66) expresses 'very mixed feelings on psychedelic inquiry' as critical commentaries emerge	Mangini, 1998
1962	The Marsh Chapel or 'Adept Friday' experiment conducted at Harvard under Timothy Leary's supervision only without institutional approving	Pahnke, 1966; Mangini, 1998
1963	Leary dismissed from Harvard; Aldous Huxley and JFK die (both on 22nd November)	Stevens, 1987
1964	Cole takes 'sober expect' at psychedelics in JAMA; discussions on LSD take centre stage at 1964 APA meeting; Ken Kesey travels across US taking LSD with 'Merry Pranksters'	Mangini, 1998; Cole and Katz, 1964; Stevens, 1987; Wolfe, 1968
1965	Sandoz stop manufacture of LSD and psilocybin	Stevens, 1987
1966	Prohibition of psychedelics and curtailment of research begins in US; Senator Robert Kennedy formally questions this move	Stevens, 1987; Lee and Shlain, 1992
1967	Timothy Leary declares 'turn on, tune in and driblet out' at festival in Golden Gate Park	Stevens, 1987
1970	President Nixon signs Controlled Substances Human activity, LSD and psilocybin made Schedule 1	Stevens, 1987; Lee and Shlain, 1992

The present revival

Human being psychedelic inquiry roughshod into a 25-year hiatus before scientists in Deutschland (Hermle et al, 1992), the The states (Strassman and Qualls, 1994), and Switzerland (Vollenweider et al, 1997) began its revival. There at present exists a foundation of man neuroimaging (Carhart-Harris et al, 2012a, 2016d; Daumann et al, 2010; Muthukumaraswamy et al, 2013; Palhano-Fontes et al, 2015; Preller et al, 2017; Riba et al, 2004, 2006; Vollenweider et al, 1997), psychology (Carhart-Harris et al, 2015, 2016c; Carter et al, 2007; Gouzoulis-Mayfrank et al, 2005; Griffiths et al, 2006; MacLean et al, 2011; Schmid et al, 2015), and psychopharmacology studies with psychedelics (Kometer et al, 2012; Preller et al, 2017; Valle et al, 2016; Vollenweider et al, 1998).

These foundational studies complement a pocket-size number of early phase clinical trials (Tabular array 2). There are now positive preliminary reports on the safety and tolerability of psilocybin for obsessive compulsive disorder (Moreno et al, 2006), psilocybin, and LSD for finish-of-life psychological distress (Gasser et al, 2014; Griffiths et al, 2016; Grob et al, 2011; Ross et al, 2016), psilocybin for alcohol (Bogenschutz et al, 2015), and tobacco addiction (Johnson et al, 2014) and ayahuasca (Osorio Fde et al, 2015) and psilocybin for major depressive disorder (Carhart-Harris et al, 2016a, b). An important caveat hither, is that many of these trials written report on small sample sizes and would best exist described equally 'safety and tolerability' studies past conventional standards (Schunemann et al, 2006), and while all of them do report outcomes consistent with potential efficacy, well-nigh take not been appropriately designed to demonstrate it conclusively. GMG critically discusses two of the largest and improve designed trials in the next department (Griffiths et al, 2016; Ross et al, 2016).

Table 2

Clinical Trials Involving Psychedelics Published During the Nowadays 'Second Wave' of Psychedelic Research

Study	Population/indication and sample size	Drug and design	Main efficacy outcome
Moreno et al (2006)	Obsessive compulsive disorder, due north=ix	Psilocybin: single-arm, within subjects, variable doses. Up to four doses of psilocybin	All patients showed improvements within 24 h of a treatment but no consequence of dose
Grob et al (2011)	Feet and depression in end-phase cancer, n=12	Psilocybin: DB-RCT, crossover, inert placebo. Single dose of psilocybin	Significant reductions in trait anxiety at 3 months and low at 6 months
Johnson et al (2014)	Long-term chronic tobacco smoking, due north=15	Psilocybin: open-label. Up to three doses of psilocybin subsequently 4 CBT sessions	80% of sample abstemious at 6 month follow-up
Gasser et al (2014)	Anxiety related to life-threatening disease, n=12	LSD: DB-RCT, crossover, very low dose (VLD) LSD=control. Unmarried dose of LSD	Significant decreases in state and trait anxiety vs VLD at ii months and sustained for 12 months
Bogenschutz et al (2015)	Booze dependence, due north=10	Psilocybin: open-label. Up to two doses after vii motivational therapy sessions	Meaning subtract in drinking behaviors for up to ix months
Osorio Fde et al (2015) and Sanches et al (2016)	Major depressive disorder (MDD), due north=six+written report extension to n=17	Ayahuasca: open-label. Single dose of ayahuasca	Significant decreases in depressive symptoms for upward to 21 days
Carhart-Harris et al (2016a, b)	Treatment-resistant MDD, due north=12+study extension to n=20	Psilocybin: open up-characterization. Ii doses of psilocybin	Meaning decreases in depressive symptoms for up to 6 months
Ross et al (2016)	Anxiety and low related to life-threatening cancer, north=29	Psilocybin: DB-RCT, crossover, niacin=active placebo. Single dose of psilocybin	Significant decreases in anxiety and depression vs niacin at 7 weeks (pre crossover) and sustained for 6.5 months
Griffiths et al (2016)	Anxiety and depression related to life-threatening cancer, n=51	Psilocybin: DB-RCT, crossover, VLD psilocybin=control. Single dose of psilocybin	Pregnant decreases in anxiety and depression vs VLD at v weeks (pre crossover). Effects sustained for 6 months

PSYCHEDELICS FOR MENTAL ILLNESS

Establish-based psychedelics take been used for hundreds if not thousands of years for holistic healing (Hofmann, 1980) and there remains an active culture of self-medication with psychedelics for mental health (Carhart-Harris and Nutt, 2010; Waldman, 2017). Contrary to the alarmist campaigning that and so negatively afflicted perceptions of psychedelics later the 1960s, subjective (Carhart-Harris and Nutt, 2010, 2013; van Amsterdam et al, 2015), naturalistic/observational (Bouso et al, 2012), and population-based data (Hendricks et al, 2015) indicate a positive association between psychedelic drug utilize and mental health, albeit with some important caveats, which will be discussed below.

Progressing to more controlled medical use, psychedelics piqued the interest of psychologists and psychiatrists in the 1950s, who noted early on that they may 'serve as new tools for shortening psychotherapy' (Busch and Johnson, 1950). A contempo meta-analysis of 19 studies of psychedelics for mood disorders published between 1949 and 1973 constitute that 79% of patients showed 'clinically judged improvement' postal service handling (Rucker et al, 2016). Moreover, a meta-assay of studies of LSD for alcoholism performed in the 50–60s was similarly supportive of its potential (Krebs and Johansen, 2012). The absenteeism of standardized diagnostic techniques, measures of symptom severity, and lack of randomization and command weather in these studies needs to exist properly heeded, merely equally, information technology would be cocky-defeating to dismiss their findings outright.

The mod era of controlled research with psychedelics has seen the adoption of more careful experimental designs, together with a more critical arroyo to outcomes. In 2006, a double-blind randomized controlled (DB-RC) report compared the acute and longer-term psychological effects of single high doses of psilocybin (xxx mg) and methylphenidate (40 mg) in healthy volunteers. Significantly, greater improvements in psychological well-being were observed after psilocybin than methylphenidate at the 2-calendar month cease point and more than than half considered their psilocybin experience to be among the almost personally meaningful experiences of their lives (Griffiths et al, 2006). Since then, the focus has shifted to include patients with symptoms of low and anxiety. Three DB-RC trials accept assessed the bear upon of a single dose of psilocybin on depressive symptoms in patients with life-threatening cancer (Griffiths et al, 2016; Grob et al, 2011; Ross et al, 2016) and an open-label trial of psilocybin for treatment-resistant low (TRD) has been completed (Carhart-Harris et al, 2016a, b). All four studies, and particularly the three most recent, found rapid, marked, and enduring anti-anxiety and depression effects mail service psilocybin. Meaning improvements in obsessive compulsive disorder symptoms (Moreno et al, 2006) and alcohol dependence with psilocybin (Bogenschutz et al, 2015), anxiety with LSD (Gasser et al, 2014), and depression with ayahuasca (Osorio Fde et al, 2015; Sanches et al, 2016) help supplement the case for psilocybin and inspire questions regarding the potential generalized therapeutic action of psychedelics.

Focusing on antidepressant activeness, psilocybin, and psychedelics more than generally, share some similarities with conventional antidepressants (ie, serotonergic modulation); notwithstanding, they likewise possess some important differences. Regarding similarities, an altered relationship with the environment may be disquisitional to recovery with selective serotonin reuptake inhibitors (Belsky, 2016; Harmer and Cowen, 2013) and heightened sensitivity to the environs is a key feature of the psychedelic state (Carhart-Harris et al, 2015; Hartogsohn, 2016; Kaelen et al, 2015), perhaps due to psychedelics' direct agonist activity at the 5-HT2AR (Dressler et al, 2016; Fiocco et al, 2007; Jokela et al, 2007). Regarding differences, the chronic antidepressant action of SSRIs includes reduced limbic responsiveness and emotional moderation or blunting, probable via postal service-synaptic 5-HT1A receptor signaling (Cowen and Browning, 2015; Deakin and Graeff, 1991; McCabe et al, 2010); this contrasts with the greater part for 5-HT2AR signaling with psychedelics, and accent on emotional release (Carhart-Harris et al, 2012b; Roseman et al, 2016; Watts et al, 2017). Contrasting approaches to emotion may exist a cardinal difference between the SSRI and psychedelic treatment models (Figure 1).

An external file that holds a picture, illustration, etc. Object name is npp201784f1.jpg

A bipartite model of serotonergic functioning focused on the effects of post-synaptic 5-HT1AR and five-HT2AR signaling. The more pronounced effects of chronically used SSRIs on post-synaptic 5-HT1AR signaling is hypothesized to relate to their anti-stress, pro-coping properties but also their tendency to moderate or 'blunt' emotional responsiveness. The direct 5-HT2AR agonist properties of psychedelics are hypothesized to relate to their proclivity to enhance sensitivity to the environs besides equally facilitate emotional release, which, when combined with psychological support, is hypothesized to be therapeutically potent.

In my opinion, if the scientific discipline is allowed to progress without the kind of political interference that has hindered it in the past, psilocybin with psychological support (PwPS) will become an early on choice in the treatment of depression. I predict that PwPS will be institute to accept of import areas of superiority over current early interventions such equally SSRIs and CBT. Specifically, PwPS's rapid and enduring action with minimal exposure, positive side-event contour, and specific therapeutic activeness—working to address rather than suppress or side-stride aversive memories and emotions, may set it apart from the alternative, largely 'palliative' handling options for major depression.

"That is the essence of science: ask an impertinent question, and you are on the mode to a pertinent answer." (Jacob Bronowski, 908–1974)

Another consideration is that chronic antidepressant medication strategies appear to have a muting effect on psilocybin's astute and putative antidepressant effects (Bonson et al, 1996; Bonson and Murphy, 1996), implying that treating medication-heavy, treatment-resistant depressed patients with psilocybin will be especially challenging (Carhart-Harris et al, 2016a, b). Medication discontinuation would likely exist required prior to receipt of the psychedelic and this often requires careful management (Baldwin et al, 2007).

The therapeutic potential of psychedelic drugs: upbeat pessimism (GMG)

"What Leary took downward with him was the central illusion of a whole life-fashion that he helped to create... a generation of permanent cripples, failed seekers, who never understood the essential old mystic fallacy of the Acrid Civilization: the desperate assumption that somebody, or at least some force, is tending the Light at the end of the tunnel." (Hunter S Thompson. Fearfulness and Loathing in Las Vegas, 1971)

Finding signal amidst the psychedelic noise

As a clinician long committed to the view that neuroscience should inform psychiatry, psychedelics have always looked like a serious opportunity. Their structure and pharmacology inspired a generation of neurochemists to sympathise neurotransmitters and their receptors. And, the very idea that drugs could usefully alter the experience of distressed patients with psychiatric disorders underpinned the revolution in psychopharmacology in the three decades from 1950. However, the 'illegal' status of psychedelics stopped serious enquiry in humans until quite recently, as RLC-H has explained.

So, tin psychedelics take us back to the futurity? I understand the appeal that RLC-H feels for their potential. However, the difficulty in finding a medical role for psilocybin must not be underestimated. Information technology is worth reflecting on what we have learned from the very recently published clinical trials. Their strengths and their weaknesses define the challenge. Every bit for the strengths, when two very similarly designed but independent studies of the effects of any pharmacological agent give the aforementioned issue, it is encouraging. Accordingly, the two studies in patients with cancer experiencing enduring psychiatric symptoms and given psilocybin or a comparator (Griffiths et al, 2016; Ross et al, 2016) deserve to exist taken seriously. However, there have to be caveats. Are we confident that we empathize the patient population? Did the trial design allow a clear question to be asked and were the outcomes meaningful?

The patient populatioN

In the selection of patient group, why cancer patients? Ross et al (2016) suggested that a domain of distress they call existential/spiritual well being is peculiarly relevant to depression in cancer while Griffith et al (2016) emphasize that evidence for efficacy of conventional medication or psychotherapy is poor or fifty-fifty negative.

Symptoms of both depression and feet are relatively common in cancer patients. But, they are oftentimes not very severe and in fact patients may cull not to seek assistance in their handling (Baker-Glenn et al, 2011). In a case series of 128 patients attention for their first session of chemotherapy for cancer, just about 20% indicated they would appreciate psychological help for distress, depression, or anxiety. Of these, most indicated they would capeesh the opportunity to speak to someone—but merely one suggested a psychiatrist.

Significant depressive symptoms can occur in cancer patients of course and active screening of a large consecutive cohort suggested about 8% met criteria for a major depressive episode (Sharpe et al, 2004) and many are not offered handling. A subsequent trial in 200 such patients was conducted to compare a nurse intervention (which included antidepressant medication as an option and problem solving) with treatment every bit usual (Strong et al, 2008). There was a clinically pregnant and sustained touch of intervention on depressive symptoms (and on anxiety and fatigue): 68% of the treated grouping achieved remission compared with 45% of the comparator group (odds ratio 3 (confidence interval: ane.6–v.5).

Thus, the case for a item unmet need in cancer patients is actually quite hard to sustain. The idea that cancer diagnosis poses a particular threat to existential/spiritual well-being in some patients may be correct but there is a take chances that one recruits into trials people with a particular interest in psychedelic experience, who are hence predisposed to endorse its benefits. They may not be representative of cancer patients in general. In the published study where it is reported, the rate of previous employ of hallucinogens was indeed high (55% in the Ross et al, 2016).

The trial blueprint

In each of the two cancer studies, the blueprint was a crossover, which compared, respectively, low-dose/high-dose psilocybin and niacin (placebo)/loftier-dose psilocybin. The subjective effects of the high dose consisted in heightened states of consciousness with marked emotional accompaniments (anxiety, tearfulness, and in a few cases, paranoid ideation). These effects were as expected, given the previous literature. It is hard to see how blinding can be maintained because the subjective furnishings of drug were then florid. There was some uncertainty in the ratings by support staff, who supervised the sessions blind to dosing. Nevertheless, overall i must assume the patients were usually unblinded by their experience on active drug. If and so, it provided the kind of cue chosen a need feature. That is anything that makes participants in an experimental study enlightened of what the experimenter expects to find or how participants are expected to bear. Such problems would besides be difficult to avoid in judging outcomes, without great intendance in preserving raters to exist blind.

THE OUTCOME MEASURES

The outcome measures of both trials are self, community, and clinician reports. Thus, they are entirely subjective, as near studies of antidepressants and anxiolytics accept been. The demand problem has been noted already for patients, but it will besides be problematic for third-party reports if patients communicate their own unblinding at interview. But, just as for other studies, symptoms lone are a problematic way of assessing outcome. In other words, they are not highly proximal to the disease procedure as for example research domain criteria dimensions accept been suggested to be. But, they are also not distal enough for assessing the functional value of treatment either. More objective measures are possible. One could considerately measure uncomplicated motor activity or geolocation. Geolocation is particularly simple to obtain entirely passively from mobile phones. The resulting measure of time at home for case correlates well with depression severity in depressed bipolar patients (Palmius et al, 2016). In cancer patients, there is the further domain of medical care, which is known to exist complicated past co-morbid depression. An increase in adherence to treatment or even efficacy could result from really effective treatment. Greater objectivity should contribute more to the picture in future inquiry of psilocybin's potential role. Nevertheless, for the moment, subjective response remains the regulatory standard against which psychotropic drugs will be measured.

DOES THE PSILOCYBIN EXPERIENCE Really BELONG IN MEDICINE?

The unspoken assumption, which I think we both share, is that the apply of psilocybin at this stage requires a medical justification. Certainly, it started in western gild as a putative aid to psychotherapy, simply of course, it has an older cultural history as a constituent of magic mushrooms. Many believed and believe that the justification for the use of such drugs lies in their chapters to open the doors of perception, as Aldous Huxley put information technology. On this view, access to such drugs should be a recreational right, like admission to booze, cigarettes, and increasingly cannabis. As with cannabis, medical use may be expected to promote wider discretionary use for any reason. Some may still regard this equally a ruby light for the development of medical indications.

However, there is an important corollary to the continuing illegal status of psychedelics. It seems to me paradoxical, even incredible, that such drugs should not be available for medical use in conditions for which euthanasia is already available. In Belgium, neuropsychiatric disorders were first reported under euthanasia legislation in 2004/v. Of the first such 100 patients considered for euthanasia between 2007 and 2011, 58 had depression. Forty-eight of the total were accepted for euthanasia (35 completed) and six others had died past suicide within 12 months from the finish of the study. Almost patients were female, aged 40–60 years. Euthanasia for psychological suffering is similarly bachelor in holland and Luxemburg (Thienpont et al, 2015).

Then, I think we need psilocybin in medicine but we should not forget the failures of human being logic, which mean we need loftier-quality clinical trials:

"All who drinkable of this remedy recover in a brusk time, except those whom it does not help, who all die. Therefore, it is obvious that it fails just in incurable cases." (Galen in 180 Advertising)

HOW TO Motion THE FIELD Forwards (GMG AND RLC-H)

Our shared interest in the evolution of psychedelics, and particularly psilocybin, for medical apply is a major betoken of convergence. There may be a subtle departure in our views of the and so-called 'mystical' elements of the psychedelic experience, ie, both of usa see the term 'mystical' every bit problematic—but whereas GMG views the acute 'psychedelic feel' as irrelevant to the clinical evolution of psychedelics, RLC-H sees information technology as a potentially exploitable component—especially as information technology has been shown to exist predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a, b). Maybe the about notable point of deviation, even so, relates to the choice of patient population for the clinical development of psilocybin for low. For GMG, the most obvious and relevant unmet demand is treatment-resistant depression (see below), and while RLC-H accepts that treatment resistance is often the starting time port-of-telephone call for the evolution of a novel intervention, he feels that unipolar depression more generally, will prove a better indication for this handling. In his view, psilocybin will be safest, nearly effective, and easiest to implement, prior to the handling-resistant stage of illness.

Focusing on handling-resistant low for the moment, withal, nosotros both recognize that a significant number of patients treated starting time line with either a SSRI or CBT fail to respond fairly (Gaynes, 2009). Persisting symptoms pb to indelible chronicity of low, and there is no consensus in existing guidelines on what to practise next. Moreover, the efficacy of secondary intervention is oft modest and new medications can introduce new side effects. The elapsing of distress with TRD and its economic impact are considerable. We agree that TRD represents a valid point in the treatment pathway, where a unmarried psychedelic intervention might find a place; nevertheless, RLC-H questions whether patients must wait until their depression is significantly stamped-in earlier psilocybin tin can exist considered, and based on the speed and duration of treatment responses seen in the trials listed in a higher place, it seems reasonable to enquire whether early intervention with psilocybin could be rubber—and there is too the issue of SSRIs obstructing the potential therapeutic action of psilocybin.

If information technology is to be TRD, nevertheless, then patient recruitment can be based on pre-existing criteria (Sackeim, 2001) and patients meeting them will non be rare and should not be excessively treatment resistant. As noted earlier, at that place is a significant claiming to the issue of continuing medication, nigh commonly with SSRIs. There is anecdotal evidence that psychedelic furnishings are largely attenuated by ongoing treatment with SSRIs (Bonson et al, 1996) and perchance with other antidepressants (Bonson and Murphy, 1996). Downregulation of 5-HT2A receptors is a feature of many different kickoff-line antidepressant drugs (Muguruza et al, 2014), as well every bit second-line antidepressant medications (eg, singular antipsychotics) with significant 5-HT2AR antagonist backdrop (Gray and Roth, 2001). Whatever trial would ideally be conducted in patients withdrawn from such drugs for at to the lowest degree 2 weeks or so, only nosotros accept that this is not always straightforward (Baldwin et al, 2007).

Moving on from questions of the optimal patient population, both of us tin run into merit in a multiple dose trial comparing, for example, 1, 10 and 25 mg of psilocybin. Such a design seems to overcome some of the problems any trial of a psychedelic volition face. The ethical trouble of equipoise seems satisfactory because we really practise not know which dose, if whatsoever, volition be effective, and patients can enter the study knowing that whatsoever group they are allocated to, they will receive active drug. The omission of a strict placebo command would exist pragmatic in this sense, equally expectation and preparation would exist standardized. Nosotros know the highest dose of psilocybin will likely unblind participants and the expectation of a possible placebo would complicate recruitment. An approximation to an inert placebo condition may exist met with the one mg psilocybin arm, as such a dose is likely too low to produce observable subjective or physiological effects (Griffiths et al, 2016). The differences between a dose mainly producing perceptual distortion (10 mg) and one more capable of producing the more profound, putatively 'transformative' aspects of the psychedelic experience (25 mg) is likewise of scientific and clinical involvement.

Comparing mechanisms and/or efficacy with an established treatment would be a side by side pace to advance the evidence base for psilocybin for TRD. For instance, psilocybin could be compared with ketamine since it has some similarities: rapid, single-dose efficacy, and obvious subjective effects during its infusion. Psilocybin's distinctive subjective effects and the implications of this for blinding would still remain a major claiming; moreover, as with ketamine, there will as well remain the question of how much an acute response is sustained and whether a maintenance dose may be required.

The traditional view of the machinery, whereby psilocybin works, emphasizes the importance of accompanying psychotherapy (Johnson et al, 2008; Richards, 2015). Appropriately, psychedelics administered without psychological support and/or a supportive surround may accept limited antidepressant efficacy, and in very rare cases, could even worsen a patient's status (Oram, 2014). We share the view that the presence of psychological support is an essential component of the psychedelic treatment model (Johnson et al, 2008) merely we also recognize that the magnitude and nature of its contribution needs to be better defined and tested.

Pragmatically, we accept that minimizing the active psychological work of the therapy would be desirable (eg, therapy time is expensive) and scientifically, doing so would allow drug effects and dose to be improve identified. Critically however, any such therapy minimization should not be allowed to jeopardize patient safety (Johnson et al, 2008). A hereafter challenge will exist to acquire how psychological interventions tin can maximize the advantages of the psychedelic state. For instance, we tin can imagine how cerebral therapy, attentional-bias training and/or de-sensitization could be investigated with or without psilocybin aid.

In other respects, a psilocybin trial is easier to conduct than studies requiring continuing adherence to a daily oral dose of an antidepressant. Exposure to the treatment can be completely controlled and follow-upwardly tin exist relatively businesslike. Information technology seems logical to determine an early proximal end betoken to evidence initial impact of treatment and then to follow subsequent illness course equally comprehensively as possible. In this manner, we will be able to make up one's mind time to supplementary treatment, certificate recovery of symptoms and function, and possibly objectify improvement using a unproblematic frictionless measure of action-similar geolocation (Palmius et al, 2016).

In the short term, there will as well be a need to demonstrate price effectiveness. The requirement for psychological support and/or a supportive environment could exist a major limitation of the psychedelic treatment model. However, direct medical costs need to be netted off against the social and economical costs of disease.

In summary, a door has been opened for the medical repurposing of psychedelics. The possibility exists that drugs like psilocybin can meet a major unmet demand in the handling of psychiatric disorders. For GMG, treatment-resistant depression is the most logical place to start considering of the dubiety effectually the choice of adjacent-step treatment after an SSRI fails, and while RLC-H accepts this (Carhart-Harris et al, 2016a, b), he looks forrad to a time when an private may receive psilocybin before the ruts of low are allowed to deepen (Holtzheimer and Mayberg, 2011). Regardless of who the 'right' patient population might be eventually, a key challenge now is to design the optimal trial to demonstrate efficacy, agree its validity with regulatory authorities and fund information technology.

Funding and disclosure

GMG is a NIHR senior investigator; the views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. GMG holds a grant from Wellcome Trust, holds shares in P1vital and has in the past iii years served as consultant, advisor or CME speaker for Angelini, MSD, Lundbeck (/Otsuka or /Takeda), Medscape, P1Vital, Pfizer, Servier and Shire. RLC-H is supported by the Alex Mosley Charitable Trust and his research has received back up from the Beckley Foundation, as part of the Beckley-Imperial Research Program. RLC-H and GMG are currently advising Compass Pathways, a commercial initiative to develop psilocybin as a medicine.

Acknowledgments

RLC-H would like to thank Samantha Stiff for the illustrations contained in Figure 1.

Footnotes

The completion of this commodity received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Abramson A (1959) The Use of LSD in Psychotherapy. Josiah Macy, Jr. Foundation: New York. [Google Scholar]
Bakery-Glenn EA, Park B, Granger 50, Symonds P, Mitchell AJ (2011). Desire for psychological back up in cancer patients with depression or distress: validation of a elementary help question. Psychooncology 20: 525–531. [PubMed] [Google Scholar]
Baldwin DS, Montgomery SA, Nada R, Lader M (2007). Discontinuation symptoms in depression and feet disorders. Int J Neuropsychopharmacol 10: 73–84. [PubMed] [Google Scholar]
Belsky J (2016). The differential susceptibility hypothesis: sensitivity to the environment for better and for worse. JAMA Pediatr 170: 321–322. [PubMed] [Google Scholar]
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015). Psilocybin-assisted handling for alcohol dependence: a proof-of-concept written report. J Psychopharmacol 29: 289–299. [PubMed] [Google Scholar]
Bonson KR, Buckholtz JW, Murphy DL (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14: 425–436. [PubMed] [Google Scholar]
Bonson KR, Murphy DL (1996). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Encephalon Res 73: 229–233. [PubMed] [Google Scholar]
Bouso JC, Gonzalez D, Fondevila S, Cutchet K, Fernandez X, Ribeiro Barbosa PC et al (2012). Personality, psychopathology, life attitudes and neuropsychological performance amongst ritual users of Ayahuasca: a longitudinal study. PLoS Ane seven: e42421. [PMC free article] [PubMed] [Google Scholar]
Bradley Lead, Elkes C, Elkes J (1953). On some effects of lysergic acid diethylamide (50.S.D. 25) in normal volunteers. J Physiol 121. [PubMed] [Google Scholar]
Busch AK, Johnson WC (1950). L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst 11: 241–243. [PubMed] [Google Scholar]
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE et al (2016. a). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. The British Clan for Psychopharmacology Summer Meeting. 17–twenty July, Brighton, UK; Abstruse.
Carhart-Harris RL, Bolstridge M, Rucker J, Solar day CM, Erritzoe D, Kaelen One thousand et al (2016. b). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry iii: 619–627. [PubMed] [Google Scholar]
Carhart-Harris RL, Erritzoe D, Williams T, Rock JM, Reed LJ, Colasanti A et al (2012. a). Neural correlates of the psychedelic state every bit determined by fMRI studies with psilocybin. Proc Natl Acad Sci U.s.a. 109: 2138–2143. [PMC gratuitous commodity] [PubMed] [Google Scholar]
Carhart-Harris RL, Kaelen G, Bolstridge Yard, Williams TM, Williams LT, Underwood R et al (2016. c). The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med 1–12. [PubMed]
Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2015). LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232: 785–794. [PubMed] [Google Scholar]
Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi North, Bargiotas T et al (2012. b). Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging report with psilocybin. Br J Psychiatry 200: 238–244. [PubMed] [Google Scholar]
Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen Thousand, Droog W, Tater Thousand et al (2016. d). Neural correlates of the LSD feel revealed by multimodal neuroimaging. Proc Natl Acad Sci USA 113: 4853–4858. [PMC complimentary commodity] [PubMed] [Google Scholar]
Carhart-Harris RL, Nutt DJ (2010). User perceptions of the benefits and harms of hallucinogenic drug utilize: a spider web-based questionnairestudy. J Subst Use 15: 283–300. [Google Scholar]
Carhart-Harris RL, Nutt DJ (2013). Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs 45: 322–328. [PubMed] [Google Scholar]
Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007). Psilocybin links binocular rivalry switch charge per unit to attention and subjective arousal levels in humans. Psychopharmacology 195: 415–424. [PubMed] [Google Scholar]
Cohen Due south (1960). Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 130.one: 30–xl. [PubMed] [Google Scholar]
Cole JO, Katz MM (1964). The psychotomimetic drugs: an overview. JAMA 187: 758–761. [PubMed] [Google Scholar]
Cowen PJ, Browning M (2015). What has serotonin to do with depression? World Psychiatry 14: 158–160. [PMC complimentary article] [PubMed] [Google Scholar]
Daumann J, Wagner D, Heekeren One thousand, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E (2010). Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol 24: 1515–1524. [PubMed] [Google Scholar]
Deakin JF, Graeff FG (1991). five-HT and mechanisms of defence. J Psychopharmacol 5: 305–315. [PubMed] [Google Scholar]
Dressler WW, Balieiro MC, Ferreira de Araujo L, Silva WA Jr, Ernesto Dos Santos J (2016). Civilization as a mediator of gene-environment interaction: cultural consonance, childhood adversity, a 2A serotonin receptor polymorphism, and depression in urban Brazil. Soc Sci Med 161: 109–117. [PubMed] [Google Scholar]
Fiocco AJ, Joober R, Poirier J, Lupien S (2007). Polymorphism of the 5-HT(2A) receptor gene: association with stress-related indices in healthy centre-aged adults. Front Behav Neurosci 1: iii. [PMC free article] [PubMed] [Google Scholar]
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T et al (2014). Rubber and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202: 513–520. [PMC free article] [PubMed] [Google Scholar]
Gaynes BN (2009). Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry lxx(Suppl vi): 10–xv. [PubMed] [Google Scholar]
Gouzoulis-Mayfrank East, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic Grand et al (2005). Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cantankerous-over written report in healthy volunteers. Pharmacopsychiatry 38: 301–311. [PubMed] [Google Scholar]
Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of v-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56: 441–451. [PubMed] [Google Scholar]
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD et al (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-bullheaded trial. J Psychopharmacol thirty: 1181–1197. [PMC free article] [PubMed] [Google Scholar]
Griffiths RR, Richards WA, McCann U, Jesse R (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283. [PubMed] [Google Scholar]
Grinspoon L, Bakalar JB (1979) Psychedelic Drugs Reconsidered. Basic Books: New York. [Google Scholar]
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL et al (2011). Airplane pilot written report of psilocybin handling for anxiety in patients with advanced-phase cancer. Curvation Gen Psychiatry 68: 71–78. [PubMed] [Google Scholar]
Grof S (1979) Realms of the Human Unconscious: Observations from LSD Research. Souvenir Press: London. [Google Scholar]
Harmer CJ, Cowen PJ (2013). 'Information technology'southward the mode that yous await at it'—a cognitive neuropsychological business relationship of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 368: 20120407. [PMC free article] [PubMed] [Google Scholar]
Hartogsohn I (2016). Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30: 1259–1267. [PubMed] [Google Scholar]
Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 29: 280–288. [PubMed] [Google Scholar]
Hermle L, Funfgeld Yard, Oepen Thousand, Botsch H, Borchardt D, Gouzoulis E et al (1992). Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32: 976–991. [PubMed] [Google Scholar]
Hofmann A (1980) LSD: My Problem Kid. McGraw-Hill: New York. [Google Scholar]
Hofmann A, Heim R, Brack A, Kobel H (1958). Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia 14: 107–109. [PubMed] [Google Scholar]
Holtzheimer PE, Mayberg HS (2011). Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34: 1–9. [PMC costless article] [PubMed] [Google Scholar]
Huxley A (1954) The Doors of Perception. On the author'southward sensations under the influence of the drug mescalin.. Chatto & Windus: London. [Google Scholar]
Huxley A (1980) Moksha: Writings on Psychedelics and the Visionary Experience. Chatto and Windus: London. pp 1931–1963. [Google Scholar]
Johnson M, Richards W, Griffiths R (2008). Human hallucinogen research: guidelines for condom. J Psychopharmacol 22: 603–620. [PMC gratuitous article] [PubMed] [Google Scholar]
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014). Airplane pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28: 983–992. [PMC costless commodity] [PubMed] [Google Scholar]
Jokela M, Keltikangas-Jarvinen 50, Kivimaki Yard, Puttonen Southward, Elovainio M, Rontu R et al (2007). Serotonin receptor 2A gene and the influence of babyhood maternal nurturance on adulthood depressive symptoms. Arch Gen Psychiatry 64: 356–360. [PubMed] [Google Scholar]
Kaelen G, Barrett FS, Roseman L, Lorenz R, Family unit North, Bolstridge M et al (2015). LSD enhances the emotional response to music. Psychopharmacology 232: 3607–3614. [PubMed] [Google Scholar]
Kometer Yard, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood country toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72: 898–906. [PubMed] [Google Scholar]
Krebs TS, Johansen PO (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-assay of randomized controlled trials. J Psychopharmacol 26: 994–1002. [PubMed] [Google Scholar]
Lee MA, Shlain B (1992) Acid Dreams: The Complete Social History of LSD: The CIA, The Sixties, and Beyond. In: Rev. Evergreen (ed). Grove Weidenfeld: New York. [Google Scholar]
MacLean KA, Johnson MW, Griffiths RR (2011). Mystical experiences occasioned past the hallucinogen psilocybin atomic number 82 to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461. [PMC free article] [PubMed] [Google Scholar]
Mangini 1000 (1998). Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 30: 381–418. [PubMed] [Google Scholar]
McCabe C, Mishor Z, Cowen PJ, Harmer CJ (2010). Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67: 439–445. [PMC free article] [PubMed] [Google Scholar]
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006). Safe, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67: 1735–1740. [PubMed] [Google Scholar]
Muguruza C, Miranda-Azpiazu P, Diez-Alarcia R, Morentin B, Gonzalez-Maeso J, Callado LF et al (2014). Evaluation of 5-HT2A and mGlu(2/3) receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. Neuropharmacology 86: 311–318. [PubMed] [Google Scholar]
Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D et al (2013). Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33: 15171–15183. [PMC gratis commodity] [PubMed] [Google Scholar]
Oram M (2014). Efficacy and enlightenment: LSD psychotherapy and the drug amendments of 1962. J Hist Med Allied Sci 69: 221–250. [PubMed] [Google Scholar]
Osorio Fde L, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L et al (2015). Antidepressant furnishings of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37: 13–twenty. [PubMed] [Google Scholar]
Pahnke WN (1966). Drugs and mysticism. Int J Parapsychol viii: 295–315. [Google Scholar]
Palhano-Fontes F, Andrade KC, Tofoli LF, Santos Ac, Crippa JAS, Hallak JEC et al (2015). The psychedelic country induced by ayahuasca modulates the activeness and connectivity of the default mode network. PLoS 1 ten: e0118143. [PMC free commodity] [PubMed] [Google Scholar]
Palmius Due north, Tsanas A, Saunders KE, Bilderbeck AC, Geddes JR, Goodwin GM et al (2016). Detecting bipolar depression from geographic location data. IEEE Trans Biomed Eng (due east-pub ahead of impress). [PMC free commodity] [PubMed]
Passie T (1996). Hanscarl leuner—pioneer of hallucinogen inquiry and psycholytic therapy. Maps Newslett 7: 46–49. [Google Scholar]
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stampfli P et al (2017). The Material of significant and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27: 451–457. [PubMed] [Google Scholar]
Riba J, Anderer P, Jane F, Saletu B, Barbanoj MJ (2004). Effects of the South American psychoactive beverage ayahuasca on regional encephalon electric action in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology l: 89–101. [PubMed] [Google Scholar]
Riba J, Romero S, Grasa E, Mena E, Carrio I, Barbanoj MJ (2006). Increased frontal and paralimbic activation post-obit ayahuasca, the pan-Amazonian inebriant. Psychopharmacology 186: 93–98. [PubMed] [Google Scholar]
Richards WA (2015) Sacred Knowledge: Psychedelics and Religious Experiences. Columbia University Press: New York. [Google Scholar]
Roberts A (2008) Albion Dreaming: A Popular History of LSD in Britain. Marshall Cavendish: London. [Google Scholar]
Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart- Harris RL (2016). Psilocybin-assisted therapy increases amygdala responsivity to fearful faces, while reducing depressive symptoms after therapy in handling-resistant depression. The British Clan for Psychopharmacology Summer Meeting. 17–twenty July, Brighton, Britain; Abstract number C32.
Ross S, Bossis A, Guss J, Agin-Liebes K, Malone T, Cohen B et al (2016). Rapid and sustained symptom reduction post-obit psilocybin handling for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol thirty: 1165–1180. [PMC free article] [PubMed] [Google Scholar]
Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH (2016). Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol xxx: 1220–1229. [PubMed] [Google Scholar]
Sackeim HA (2001). The definition and significant of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16): 10–17. [PubMed] [Google Scholar]
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L et al (2016). Antidepressant furnishings of a single dose of ayahuasca in patients with recurrent low: a SPECT report. J Clin Psychopharmacol36: 77–81.. [PubMed]
Schmid Y, Enzler F, Gasser P, Grouzmann Eastward, Preller KH, Vollenweider FX et al (2015). Astute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78: 544–553. [PubMed] [Google Scholar]
Sessa B (2012) The Psychedelic Renaissance: Reassessing the Part of Psychedelic Drugs in 21st Century Psychiatry and Society. Muswell Hill Press: London. [Google Scholar]
Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A et al (2004). Major depression in outpatients attending a regional cancer middle: screening and unmet treatment needs. Br J Cancer 90: 314–320. [PMC free article] [PubMed] [Google Scholar]
Schunemann HJ, Fretheim A, Oxman Advertizement (2006). Improving the utilize of enquiry evidence in guideline development: ix. Grading evidence and recommendations. Health Res Policy Syst four: 21. [PMC complimentary commodity] [PubMed] [Google Scholar]
Stevens J (1987) Storming Heaven: LSD and the American Dream. Paladin: London. [Google Scholar]
Strassman RJ, Qualls CR (1994). Dose-response report of N,North-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51: 85–97. [PubMed] [Google Scholar]
Stoll W (1947). Lysergsäure-diäthyl-amid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neur 60: 1–2. [Google Scholar]
Strong Five, Waters R, Hibberd C, Murray Grand, Wall L, Walker J et al (2008). Direction of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 372: twoscore–48. [PubMed] [Google Scholar]
Thienpont Fifty, Verhofstadt M, Van Loon T, Distelmans Due west, Audenaert K, De Deyn PP (2015). Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open five: e007454. [PMC free article] [PubMed] [Google Scholar]
Valle M, Maqueda AE, Rabella G, Rodriguez-Pujadas A, Antonijoan RM, Romero S et al (2016). Inhibition of blastoff oscillations through serotonin-2A receptor activation underlies the visual furnishings of ayahuasca in humans. Eur Neuropsychopharmacol 26: 1161–1175. [PubMed] [Google Scholar]
van Amsterdam J, Nutt D, Phillips L, van den Brink Due west (2015). European rating of drug harms. J Psychopharmacol 29: 655–660. [PubMed] [Google Scholar]
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357–372. [PubMed] [Google Scholar]
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-two agonist action. Neuroreport 9: 3897–3902. [PubMed] [Google Scholar]
Waldman AA (2017). A really good day: how microdosing fabricated a mega difference in my mood, my union, and my life. Knopf Publishing Group: New York.
Wasson RG (1957). Seeking the magic mushroom. LIFE Magazine 49: 100–102. [Google Scholar]
Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017). Patients' accounts of increased 'connection' and 'acceptance' after psilocybin for handling-resistant depression. J Hum Psychol (in press).
Wolfe T (1968) The Electric Kool-Aid Acrid Examination. Farrar, Straus and Giroux: New York. [Google Scholar]

Articles from Neuropsychopharmacology are provided hither courtesy of Nature Publishing Group

andersontheshe.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603818/